This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Bono, J. S. Articles by Gualberto, A. Search for Related Content PubMed PubMed Citation Articles by de Bono, J. S. Articles by Gualberto, A.

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

Authors' Affiliations: ¹ Royal Marsden NHS Foundation Trust, London, United Kingdom; ² Mayo Clinic, Rochester, Minnesota; ³ McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada; ⁴ Pfizer Global Research & Development, New London, Connecticut; and ⁵ Immunicon Corporation, Huntingdon Valley, Pennsylvania

Requests for reprints: Johann S. de Bono, Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. Phone: 44-20-8722-4028; Fax: 44-20-8642-7979; E-mail: johann.de-bono{at}icr.ac.uk.

Purpose: To detect insulin-like growth factor-IR (IGF-IR) on circulating tumor cells (CTC) as a biomarker in the clinical development of a monoclonal human antibody, CP-751,871, targeting IGF-IR.

Experimental Design: An automated sample preparation and analysis system for enumerating CTCs (CellTracks) was adapted for detecting IGF-IR–positive CTCs with a diagnostic antibody targeting a different IGF-IR epitope to CP-751,871. This assay was used in three phase I trials of CP-751,871 as a single agent or with chemotherapy and was validated using cell lines and blood samples from healthy volunteers and patients with metastatic carcinoma.

Results: There was no interference between the analytic and therapeutic antibodies. Eighty patients were enrolled on phase I studies of CP-751,871, with 47 (59%) patients having CTCs detected during the study. Before treatment, 26 patients (33%) had CTCs, with 23 having detectable IGF-IR–positive CTCs. CP-751,871 alone, and CP-751,871 with cytotoxic chemotherapy, decreased CTCs and IGF-IR–positive CTCs; these increased toward the end of the 21-day cycle in some patients, falling again with retreatment. CTCs were commonest in advanced hormone refractory prostate cancer (11 of 20). Detectable IGF-IR expression on CTCs before treatment with CP-751,871 and docetaxel was associated with a higher frequency of prostate-specific antigen decline by >50% (6 of 10 versus 2 of 8 patients). A relationship was observed between sustained decreases in CTC counts and prostate-specific antigen declines by >50%.

Conclusions: IGF-IR expression is detectable by immunofluorescence on CTCs. These data support the further evaluation of CTCs in pharmacodynamic studies and patient selection, particularly in advanced prostate cancer.

This article has been cited by other articles:

				W. W. Ma and A. A. Adjei Novel Agents on the Horizon for Cancer Therapy CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137. [Abstract] [Full Text] [PDF]

				C. Massard, A. Chauchereau, and K. Fizazi The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer Ann. Onc., February 1, 2009; 20(2): 197 - 199. [Full Text] [PDF]

				H. Schwarzenbach, C. Alix-Panabieres, I. Muller, N. Letang, J.-P. Vendrell, X. Rebillard, and K. Pantel Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer Clin. Cancer Res., February 1, 2009; 15(3): 1032 - 1038. [Abstract] [Full Text] [PDF]

				J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W.W.M. Terstappen, K. J. Pienta, and D. Raghavan Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6302 - 6309. [Abstract] [Full Text] [PDF]

				J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials Mol. Cancer Ther., September 1, 2008; 7(9): 2575 - 2588. [Abstract] [Full Text] [PDF]

				S. J. Cohen, C. J.A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., July 1, 2008; 26(19): 3213 - 3221. [Abstract] [Full Text] [PDF]

				M C. Miller, G. V Doyle, and L. W M M Terstappen Monitoring and Characterization of CTC in Cancer Patients Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 617 - 624. [Abstract] [Full Text] [PDF]

				C. P. Carden, D. Olmos, and J. S. de Bono Validated and Qualified Biomarkers Are Critical to Optimizing Anticancer Drug Development: Potential Roles for the Study of Circulating Tumor Cells ASCO Educational Book, January 1, 2008; 2008(1): 166 - 170. [Abstract] [Full Text] [PDF]

				P. Haluska, H. M. Shaw, G. N. Batzel, D. Yin, J. R. Molina, L. R. Molife, T. A. Yap, M. L. Roberts, A. Sharma, A. Gualberto, et al. Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5834 - 5840. [Abstract] [Full Text] [PDF]